Drug News

Key Market Analysis of Sickle Cell Disease, Fanconi Anemia, and Diamond-Blackfan Anemia in the Inherited Types of Anemia Therapeutic Space

Overview: Anemia, a significant public health challenge, affects various demographic groups, including young children, pregnant and postpartum women, and menstruating adolescent girls. Globally, around 40% of children aged 6 to 59 months, 37% of expectant mothers, and 30% of women between 15 and 49 years suffer from anemia. Inherited types of anemia, characterized by genetic disorders affecting hemoglobin production, structure, or function, pose a lifelong challenge requiring comprehensive medical care.

DelveInsight Reports: DelveInsight’s recent epidemiology-based market reports focus on inherited anemias such as Sickle Cell Disease, Fanconi Anemia, and Diamond-Blackfan Anemia. These reports provide insights into treatment practices, emerging drugs, market share of individual therapies, and current/future market sizes from 2019 to 2032 in the United States, EU-4 (Italy, Spain, France, Germany), the United Kingdom, and Japan.

Sickle Cell Disease Market:

•          SCD is a group of inherited conditions impacting hemoglobin structure, leading to chronic hemolytic disorder.

•          DelveInsight’s analysis indicates ~105K prevalent cases of SCD in the US in 2022, projected to increase by 2032.

•          Treatment involves pain alleviation, infection risk reduction, and complication management.

•          FDA-approved drugs include hydroxyurea, ENDARI, ADAKVEO, and OXBRYTA.

•          Emerging therapies like Exa-cel, Lovo-cel, GBT-601, Mitapivat, and others aim for holistic cures.

•          The US market was ~USD 700 million in 2022, expected to grow by 2032.

Fanconi Anemia Market:

•          Fanconi anemia disrupts bone marrow function, leading to blood cell deficiencies and an elevated cancer risk.

•          DelveInsight estimates 6.7K diagnosed prevalent cases globally in 2021, with the US having the highest count.

•          Treatment is tailored to individual symptoms, requiring a multidisciplinary medical team.

•          The pipeline includes RP-L102 (lentiviral gene therapy) and FP-045.

•          The market is predicted to increase from USD 45 million in 2021, with expected growth due to improved understanding, awareness, and research.

Diamond-Blackfan Anemia Market:

•          DBA is a rare inherited blood disorder causing a severe shortage of red blood cells.

•          Prevalence is around 5 to 7 cases per million live births.

•          Treatment focuses on managing anemia through blood transfusions, corticosteroids, and, in some cases, stem cell transplantation.

•          The market is expected to grow due to increased awareness, genetic research advancements, and regulatory incentives.

•          Research initiatives and collaborations aim to develop novel therapies, including gene therapies and small molecules.

Other Trending Hematological Disorders Reports:

•          Warm Autoimmune Hemolytic Anemia Market

•          Multiple Myeloma Market

•          Hemophilia Market

•          Beta-Thalassemia Market

•          Cold Agglutinin Disease Market

About DelveInsight: DelveInsight is a healthcare-focused market research and consulting firm providing high-quality market intelligence and analysis. With expertise in life sciences and healthcare, they offer customized research solutions globally.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker